Nasdaq Confirms POMDOCTOR Meets Bid-Price Rule

POMDOCTOR regained compliance with Nasdaq's $1 minimum bid price while facing two separate market value deficiency notices.

Updated on Nov. 9, 2026 in Public Companies

Bold flat-color editorial illustration of two stacked steel weights on a concrete plinth, one leaning against the other, in deep red and cream.
Nasdaq confirmed POMDOCTOR regained compliance with its $1 minimum bid price on November 5, while still facing two market value deficiency notices. AI Illustration. Upload story photo >

Nasdaq confirmed that POMDOCTOR Class A ordinary shares met the $1 minimum bid-price requirement on November 5, 2026. The exchange also notified the company that it fell below two market value listing standards, with shares continuing to trade under the ticker POM.

Why it matters

The bid-price confirmation removes one listing deficiency, but the market value notices mean POMDOCTOR must still address separate requirements to remain listed on Nasdaq. Public companies that fall below these thresholds face potential delisting if they cannot restore compliance.

Nasdaq's notices cite a $50 million market value of listed securities standard and a $15 million market value of publicly held shares standard, each measured over 30 consecutive business days. POMDOCTOR has until April 26, 2027, to meet both requirements, but the filing does not describe how the company intends to do so.

The players

Nasdaq

The Nasdaq Stock Market is a major U.S. securities exchange that sets and enforces the continued listing standards companies must meet to keep their shares traded on its platform.

POMDOCTOR

POMDOCTOR is a company whose Class A ordinary shares trade on Nasdaq under the ticker POM, and it is the subject of the exchange's compliance notices.

The details

Nasdaq notified POMDOCTOR on October 6, 2026, that its closing bid had stayed below $1 for 30 consecutive business days, and it confirmed compliance on November 5. Separately, on October 28, the exchange notified the company it had fallen below both the market value of listed securities and market value of publicly held shares standards, and a Hearings Panel session scheduled for November 12 was canceled.

Timeline

  1. August 24 through October 5, 2026: closing bid stayed below $1 for 30 consecutive business days.

  2. September 16 through October 27, 2026: market value notices covered 30 consecutive business days.

  3. October 6, 2026: Nasdaq notified POMDOCTOR of the bid-price deficiency.

  4. October 28, 2026: Nasdaq notified POMDOCTOR of two market value deficiencies.

  5. November 5, 2026: Nasdaq confirmed bid-price compliance.

Market Landscape

Nasdaq's Listing Rule 5450(a)(1) sets a $1 minimum bid price that companies must sustain, and POMDOCTOR's case shows how those thresholds are enforced in practice. Companies that trigger several deficiencies at once must address each standard on its own timeline, as the April 26, 2027 deadline for the market value requirements illustrates.

For investors holding POM, the bid-price confirmation means the shares remain listed on Nasdaq for now, but the outstanding market value deficiencies create continued exposure to a possible delisting. Shareholders should watch for filings showing how the company plans to restore compliance before the April 2027 deadline.

The takeaway

A stock regaining the $1 bid-price minimum does not end a listing review when other market value standards remain unmet. Investors should track the full set of exchange requirements, not just the single notice that gets resolved first.

What happens next

POMDOCTOR must meet the market value of listed securities and publicly held shares requirements by April 26, 2027, to avoid delisting.

Further reading

For more on how listed companies handle exchange requirements, see Public Companies.

Source note: This article includes information reported by TokenPost.